TRML (Tourmaline Bio) Scaled Net Operating Assets : 0.11 (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Tourmaline Bio's operating assets for the quarter that ended in Sep. 2024 was $46.52 Mil. Tourmaline Bio's operating liabilities for the quarter that ended in Sep. 2024 was $7.09 Mil. Tourmaline Bio's Total Assets for the quarter that ended in Jun. 2024 was $344.79 Mil. Therefore, Tourmaline Bio's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.11.

Tourmaline Bio Scaled Net Operating Assets Historical Data

The historical data trend for Tourmaline Bio's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio Scaled Net Operating Assets Chart

Tourmaline Bio Annual Data

Trend

Dec21

Dec22

Dec23

Scaled Net Operating Assets

-1.51

-183.24

0.28

Tourmaline Bio Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Scaled Net Operating Assets	Get a 7-Day Free Trial						-0.04	0.02	0.29	0.14	0.11

Competitive Comparison of Tourmaline Bio's Scaled Net Operating Assets

For the Biotechnology subindustry, Tourmaline Bio's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tourmaline Bio's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tourmaline Bio's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Tourmaline Bio's Scaled Net Operating Assets falls into.

Tourmaline Bio Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Tourmaline Bio's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(7.344	-	4.838)	/	9.098
=	0.28

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	210.295	-	202.951
=	7.344

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	5.253	-	0.194	-	0.221
=	4.838

Tourmaline Bio's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Sep. 2024 )
=	(Operating Assets (Q: Sep. 2024 )	-	Operating Liabilities (Q: Sep. 2024 ))	/	Total Assets (Q: Jun. 2024 )
=	(46.523	-	7.089)	/	344.791
=	0.11

where

	Operating Assets		(Q: Sep. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	328.447	-	281.924
=	46.523

	Operating Liabilities		(Q: Sep. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	7.379	-	0.064	-	0.226
=	7.089

Tourmaline Bio Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Tourmaline Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

27 West 24th Street, Suite 702, New York, NY, USA, 10010

Website

https://www.tourmalinebio.com

Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.